RenovoRx and Imugene Announce Collaboration to Deliver Oncolytic Virus Therapy Using Proprietary Trans-Arterial Micro-Perfusion (TAMP™) Platform

Director and CEO of Imugene. “We are excited to collaborate with RenovoRx to explore the potential of combining these innovative therapies and improve outcomes for patients in need.” RenovoRx’s TAMP platform is a minimally invasive procedure that delivers therapeutic agents directly to tumors through the blood vessels, allowing for targeted treatment. This approach overcomes the limitations of t..